Related Experiment Video
Updated: Nov 16, 2025
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug
Huilin Ma1, Minu Pilvankar2, Jun Wang2
1Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States.
Abstract:
Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, translational challenges remain for preclinical studies such as study design and the relevance of animal models to humans. Hence, only a small fraction of cancer patients showed response. The explosion of drug candidates and therapies makes preclinical assessment of every plausible option impossible, but it can be easily tested using Quantitative System Pharmacology (QSP) models. Here, we developed a QSP model for humanized mice. Tumor growth dynamics, T cell dynamics, cytokine release, immune checkpoint expression, and drug administration were modeled and calibrated using experimental data. Tumor growth inhibition data were used for model validation. Pharmacokinetics of T cell engager (TCE), tumor growth profile, T cell expansion in the blood and infiltration into tumor, T cell dissemination from primary tumor, cytokine release profile, and expression of additional PD-L1 induced by IFN-γ were modeled and calibrated using a variety of experimental data and showed good consistency. Mouse-specific response to T cell engager monotherapy also showed the key features of in vivo efficacy of TCE. This novel QSP model, designed for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice, incorporating the most critical components of the mouse model with key cancer and immune cells, can become an integral part of preclinical drug development.
Insights
Quantitative Systems Pharmacology (QSP) models offer a solution to assess cancer immunotherapies in humanized mice. This new QSP model accurately predicts T cell engager efficacy in preclinical drug development.
Area of Science:
- Immunotherapy
- Preclinical Cancer Research
- Computational Biology
Background:
- Immunotherapy has advanced cancer treatment, but preclinical models face translational challenges.
- Assessing numerous drug candidates is difficult with traditional animal testing.
- Quantitative Systems Pharmacology (QSP) offers a computational approach for drug development.
Purpose of the Study:
- To develop and validate a QSP model for humanized mice to predict cancer immunotherapy efficacy.
- To integrate key biological components of the mouse model for accurate preclinical assessment.
Main Methods:
- Developed a QSP model for humanized mice, incorporating tumor and immune cell dynamics.
- Modeled T cell dynamics, cytokine release, immune checkpoint expression, and drug administration.
- Calibrated and validated the model using experimental data, including tumor growth inhibition and pharmacokinetics of T cell engagers (TCEs).
Main Results:
- The QSP model demonstrated good consistency in predicting TCE pharmacokinetics, tumor growth, T cell behavior, and cytokine profiles.
- Modeled mouse-specific responses to TCE monotherapy reflected key features of *in vivo* efficacy.
- The model successfully incorporated critical components of humanized mouse models for cancer research.
Conclusions:
- This novel QSP model for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice is a valuable tool for preclinical drug development.
- The model can aid in the efficient assessment of novel cancer immunotherapies.
- It represents an integral part of the preclinical assessment pipeline, improving translational success rates.
